Extrahepatic malignancies - particularly colorectal, breast, and pancreatic cancer - are more common in MASLD patients independent of metabolic syndrome components [3-5]
Plaintiffs point to pre-approval clinical trials and post-marketing adverse event reports that accumulated evidence of severe gastrointestinal complications years before manufacturers updated warning labels to reflect these serious risks
If youre considering a GLP-1, your healthcare team can help you understand how it fits into your overall health plan and what benefits you can expect
Nonetheless, the financial burden obesity places on healthcare systems is significant
Research on human growth hormone confirms the pattern: maximum serum concentration arrived at 4.26 hours from the abdomen versus 5.89 hours from the thigh
GLP-2 and GIP exert separate effects on bone turnover: a randomized, placebo-controlled, crossover study in healthy young men